Literature DB >> 2113446

Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions.

T Matsubara1, S Furukawa, K Yabuta.   

Abstract

We investigated 45 patients with Kawasaki disease (KD) and report the first simultaneous determination of tumor necrosis factor (TNF), interleukin 2 receptor (IL-2R) and interferon-gamma (IFN-gamma) in the serum during acute phase. Serum levels of TNF were measured by a sandwich enzyme-linked immunosorbent assay. Serum levels of soluble IL-2R and IFN-gamma were measured by a sandwich enzyme immunoassay and radioimmunoassay, respectively. Serum levels of TNF, IL-2R, and IFN-gamma were seen to increase during the acute phase of KD. In KD patients with coronary-artery lesions (CAL), the percentage of positive cases for TNF (greater than or equal to 10 U/ml), IL-2R (greater than or equal to 1056 U/ml), and IFN-gamma (greater than or equal to 0.3 U/ml) was higher than that in patients without CAL. Our results suggest that aggressive activation of immunocompetent cells develops in KD with CAL.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2113446     DOI: 10.1016/0090-1229(90)90166-n

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  71 in total

1.  CD14+CD16+ monocyte subpopulation in Kawasaki disease.

Authors:  K Katayama; T Matsubara; M Fujiwara; M Koga; S Furukawa
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

2.  Th1 and Th2 cytokine production is suppressed at the level of transcriptional regulation in Kawasaki disease.

Authors:  J Kimura; H Takada; A Nomura; T Ohno; Y Mizuno; M Saito; K Kusuhara; T Hara
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

3.  Plasma exchange for refractory Kawasaki disease.

Authors:  Tomoyuki Imagawa; Masaaki Mori; Takako Miyamae; Shuichi Ito; Tomoko Nakamura; Kiyoshi Yasui; Hirokazu Kimura; Shumpei Yokota
Journal:  Eur J Pediatr       Date:  2004-02-18       Impact factor: 3.183

4.  Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.

Authors:  Jane C Burns; Brookie M Best; Asuncion Mejias; Lynn Mahony; David E Fixler; Hasan S Jafri; Marian E Melish; Mary Anne Jackson; Basim I Asmar; David J Lang; James D Connor; Edmund V Capparelli; Monica L Keen; Khalid Mamun; Gregory F Keenan; Octavio Ramilo
Journal:  J Pediatr       Date:  2008-07-30       Impact factor: 4.406

5.  Serum soluble CD4 and CD8 levels in Kawasaki disease.

Authors:  S Furukawa; T Matsubara; K Tsuji; T Motohashi; K Okumura; K Yabuta
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

6.  Regulation of oxidative stress in patients with Kawasaki disease.

Authors:  Kaori Sekine; Hiroyuki Mochizuki; Yoshinari Inoue; Tohru Kobayashi; Eisuke Suganuma; Shinichi Matsuda; Hirokazu Arakawa
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

7.  Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients.

Authors:  Akira Hachiya; Norimoto Kobayashi; Satoshi Matsuzaki; Yusuke Takeuchi; Yohei Akazawa; Tomonari Shigemura; Noriko Motoki; Junya Masumoto; Kazunaga Agematsu
Journal:  Clin Rheumatol       Date:  2018-01-04       Impact factor: 2.980

8.  Kawasaki disease differs from anaphylactoid purpura and measles with regard to tumour necrosis factor-alpha and interleukin 6 in serum.

Authors:  S Furukawa; T Matsubara; K Yone; Y Hirano; K Okumura; K Yabuta
Journal:  Eur J Pediatr       Date:  1992-01       Impact factor: 3.183

9.  Infliximab treatment for pediatric refractory Kawasaki disease.

Authors:  Laura L Blaisdell; Jennifer A Hayman; Adrian M Moran
Journal:  Pediatr Cardiol       Date:  2011-07-20       Impact factor: 1.655

10.  Inhibition of IL-12 synthesis of peripheral blood mononuclear cells (PBMC) stimulated with a bacterial superantigen by pooled human immunoglobulin: implications for its effect on Kawasaki disease (KD).

Authors:  Y Takata; S Seki; H Dobashi; S Takeshita; K Nakatani; Y Kamezawa; H Hiraide; I Sekine; S Yoshioka
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.